Drug Repositioning for the Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Mechanism- and Screening-Based Strategy

Shota Yamamoto¹ and Nobuaki Egashira²*

¹Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan, ²Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan

Chemotherapy-induced peripheral neuropathy (CIPN) is a severe adverse effect observed in most patients treated with neurotoxic anti-cancer drugs. Currently, there are no therapeutic options available for the prevention of CIPN. Furthermore, few drugs are recommended for the treatment of existing neuropathies because the mechanisms of CIPN remain unclear. Each chemotherapeutic drug induces neuropathy by distinct mechanisms, and thus we need to understand the characteristics of CIPN specific to individual drugs. Here, we review the known pathogenic mechanisms of oxaliplatin- and paclitaxel-induced CIPN, highlighting recent findings. Cancer chemotherapy is performed in a planned manner; therefore, preventive strategies can be planned for CIPN. Drug repositioning studies, which identify the unexpected actions of already approved drugs, have increased in recent years. We have also focused on drug repositioning studies, especially for prevention, because they should be rapidly translated to patients suffering from CIPN.

Keywords: chemotherapy, chemotherapy-induced peripheral neuropathy, drug repositioning, neuropathic pain, oxaliplatin, paclitaxel

INTRODUCTION

Chemotherapy-induced peripheral neuropathy (CIPN) is a severe and dose-limiting adverse effect of neurotoxic chemotherapeutic agents. CIPN can limit the dosages and choices of drugs, and in serious cases, it leads to discontinuation of treatment. Anti-cancer drugs that often cause CIPN include platinum derivatives, taxanes, vinca alkaloids, and bortezomib. Most cases of CIPN are characterized by numbness, tingling, pain, and impaired sensory functions in the hands and feet. In particular, pain

Abbreviations: ASCO, American Society of Clinical Oncology; CB2, cannabinoid type 2 receptor; CIPN, chemotherapy-induced peripheral neuropathy; CNS, central nervous system; CYP2J, cytochrome-P450-epoxygenase 2J; DRG, dorsal root ganglia; GLP-1, glucagon-like peptide-1; IL, interleukin; LPA, lysophosphatidic acid; NFAT, nuclear factor of activated T-cell; NMDAR, N-methyl-D-aspartate receptor; Nrf2, nuclear factor-erythroid-2-related factor 2; OATP1B2, organic aniontransporting polypeptide B2; OCT2, organic cation transporter 2; RvD, resolvin D; SPMs, specialized pro-resolving mediators; S1P, sphingosine 1-phosphate; TKI, tyrosine kinase inhibitor; TRPA, transient receptor potential ankyrin; TRPM, transient receptor potential melastatin; TRPV, transient receptor potential vanilloid.
symptoms indicate mechanistic and cold allodynia, and the time of onset can range from acute (within hours) to chronic (after repeated treatments) (Mantyh, 2006; Park et al., 2013). According to the American Society of Clinical Oncology (ASCO) clinical practice guidelines released in 2014 and 2020, there are no highly recommended agents for the prevention or treatment of existing CIPN (Hershman et al., 2014; Loprinzi et al., 2020).

Numerous studies using rodent models have reported various events occurring in the dorsal root ganglia (DRG) and the spinal cord after chemotherapy, such as ion channel dysfunction, axonal degeneration of the sciatic nerve, impaired mitochondrial function, and excessive oxidative stress. Of note, taxanes cause more severe inflammatory events compared with platinum derivatives. Despite similar phenotypes, each chemotherapeutic drug induces CIPN via different mechanisms. Therefore, it is important to understand the drug-specific pathogenic mechanisms and to develop measures against each CIPN.

In clinical practice, several drugs are used for CIPN, such as pregabalin, tricyclic antidepressants, and serotonin-noradrenaline reuptake inhibitors. In addition, there are now many clinical trials investigating the effectiveness of approved drugs against CIPN (Brewer et al., 2016; Cavaletti and Marmiroli, 2020). However, most of these available drugs were shown to have poor efficacy, except for duloxetine, which is moderately recommended for the treatment of existing CIPN (Hershman et al., 2014; Loprinzi et al., 2020). Although several drugs, such as metformin and venlafaxine were reported to be effective against CIPN, confirmation is needed (Durand et al., 2012; El-Fatatry et al., 2018). Therefore, it is important to elucidate novel mechanisms based on target molecules for drug development. However, safety concerns can prevent validation of the analgesic potential of candidate agents against CIPN as well as other pain symptoms. Drug repositioning represents an alternative approach to mitigate for safety issues (Sisignano et al., 2016b). Drug repositioning studies attempt to identify unexpected actions with approved drugs used in clinical practice. This approach can reduce the duration and cost of drug development because the pharmacokinetics and safety of approved drugs have already been examined in humans. Therefore, drug repositioning is rapidly translated to patients who are suffering from CIPN.

Neuropathic pain is often caused by damage to the nervous system such as trauma, cancer, diabetes, virus infection, autoimmune disease, or chemotherapy (Colloca et al., 2017). Except for chemotherapy, most of these conditions occur unexpectedly, and therefore a number of studies are investigating the mechanisms of intractable pain to develop novel therapeutic drugs. However, because cancer chemotherapy is scheduled and administered via a regimen, CIPN is the only neuropathic pain that can be prevented. Therefore, drug-repositioning studies are a promising strategy to manage preventable neuropathic pain.

In this review, we summarize the growing evidence surrounding oxaliplatin- and paclitaxel-induced CIPN, including the mechanisms of onset and potential treatments in rodent models. We also highlight recent findings, with a focus on drug repositioning studies. Detailed information about the developmental mechanisms or clinical aspects of CIPN has been reported in previous excellent reviews (Cavaletti and Marmiroli, 2010; Hershman et al., 2014; Sisignano et al., 2014; Loprinzi et al., 2020).

**METHODOLOGY**

We searched using the terms “oxaliplatin neuropathy,” “oxaliplatin neurotoxicity,” “paclitaxel neuropathy,” and “paclitaxel neurotoxicity” in PubMed. Articles related to CIPN pathology and drug repositioning studies for the prevention and/or treatment of CIPN using cellular models or animal models were manually selected based on originality and relevance to the scope of this review. We excluded the articles written in a language other than English.

**MECHANISMS OF CIPN**

**Oxaliplatin-Induced CIPN**

Oxaliplatin is a platinum-based anticancer drug widely used as a first-line treatment for colorectal, gastric, and pancreatic cancers. Although oxaliplatin is highly effective for the treatment of cancers, it often causes severe neuropathic symptoms that can be divided into two types: acute-onset cold hypersensitivity within a few days after treatment and chronic sensory neuropathy including tactile allodynia and nummness occurring after repeated treatments. Oxaliplatin is metabolized to oxalate and dichloro (1,2-diaminocyclohexane)platinum (II) (Pt (DACH)Cl₂), which are involved in acute cold hypersensitivity and chronic neuropathy, respectively (Sakurai et al., 2009). Oxaliplatin affects the expression level and/or function of ion channels and induces excessive neuronal excitation, oxidative stress, and neurodegeneration through multiple mechanisms (Figure 1).

**Ion Channel Dysregulation**

Oxaliplatin-induced cold hypersensitivity is mainly caused by the alteration of ion channel activity, and is often recognized as a channelopathy. Oxalate is a chelator of intracellular Ca²⁺ (Grolleau et al., 2001) that disturbs neuronal membrane potentials followed by the dysregulation of voltage-gated ion channel activity. Oxaliplatin treatment alters the activities of voltage-gated ion channels and ligand-gated ion channels such as transient receptor potential (TRP) channels. Cold responsible subtypes, TRP melastatin 8 (TRPM8) and TRP ankyrin 1 (TRPA1), also contribute to oxaliplatin-induced cold hypersensitivity (Gauchan et al., 2009; Nassini et al., 2011; Zhao et al., 2012; Trevisan et al., 2013). TRPM8 expression in the DRG is upregulated early after oxaliplatin (or oxalate) infusion via a nuclear factor of activated T-cell (NFAT)-dependent mechanism, which is attenuated by blocking L-type calcium channels (Kawashiri et al., 2012). Furthermore, a recent study demonstrated that oxaliplatin inhibited prolyl hydroxylase, an enzyme that hydroxylates proline in the N-terminal ankyrin repeat of TRPA1, which leads to the enhanced sensitivity of TRPA1 (Miyake et al., 2016). In addition, it has been reported...
Mechanisms of oxaliplatin-induced peripheral neuropathy. Oxaliplatin is metabolized to oxalate and Pt(DACH)Cl₂, under the presence of physiological chloride. The red up arrows indicate an increase and/or activation, and the blue down arrows indicate a decrease and/or inhibition. Abbreviations: β-secretase 1 (BACE1); Ca²⁺/calmodulin dependent protein kinase II (CaMKII); voltage-gated calcium channel (Cav); copper transporter 1 (CTR1); glutamate transporter 1 (GLT-1); hyperpolarization-activated cyclic nucleotide-gated cation channel (HCN); multidrug and toxic compound extrusion 1 (MATE1); voltage-gated sodium channel (Nav); nuclear factor of activated T-cell (NFAT); N-methyl-d-aspartate receptor (NMDAR); neuregulin 1 (NRG1); organic cation/carnitine transporter 1 (OCTN1); prolyl hydroxylase (PHD); reactive oxygen species (ROS); satellite glial cell (SGC); potassium channel subfamily K member 4 (TRAAK); potassium channel subfamily K member 2 (TREK1); transient receptor potential channel (TRP).

FIGURE 1 | Mechanisms of oxaliplatin-induced peripheral neuropathy. Oxaliplatin is metabolized to oxalate and Pt(DACH)Cl₂, under the presence of physiological chloride. The red up arrows indicate an increase and/or activation, and the blue down arrows indicate a decrease and/or inhibition. Abbreviations: β-secretase 1 (BACE1); Ca²⁺/calmodulin dependent protein kinase II (CaMKII); voltage-gated calcium channel (Cav); copper transporter 1 (CTR1); glutamate transporter 1 (GLT-1); hyperpolarization-activated cyclic nucleotide-gated cation channel (HCN); multidrug and toxic compound extrusion 1 (MATE1); voltage-gated sodium channel (Nav); nuclear factor of activated T-cell (NFAT); N-methyl-d-aspartate receptor (NMDAR); neuregulin 1 (NRG1); organic cation/carnitine transporter 1 (OCTN1); prolyl hydroxylase (PHD); reactive oxygen species (ROS); satellite glial cell (SGC); potassium channel subfamily K member 4 (TRAAK); potassium channel subfamily K member 2 (TREK1); transient receptor potential channel (TRP).
that oxaliplatin treatment lowers the cytosolic pH of DRG neurons through binding to neuronal hemoglobin, which acts as a proton buffer. This acidification sensitizes TRPA1, which in turn leads to the development of cold hypersensitivity after oxaliplatin administration (Riva et al., 2018; Potenzieri et al., 2020).

Several other cold-sensing ion channels are also involved in oxaliplatin-induced cold neuropathy (Pereira et al., 2014; Resta et al., 2018). The expression of two distinct potassium channels, TREK1 and TRAAK, are lowered by oxaliplatin. In contrast, oxaliplatin increases the expression of hyperpolarization-activated channels (also known as HCN channels) (Descoeur et al., 2011). This remodeling of ion channel expression patterns promotes the development of oxaliplatin-induced cold hypersensitivity.

Mitochondrial Dysfunction and Oxidative Stress
Oxaliplatin causes morphological changes and functional deficits of mitochondria. The number of swollen and vacuolated mitochondria was increased in the peripheral nerves after oxaliplatin treatment (Xiao et al., 2012). In addition, multiple oxaliplatin administrations decrease O2 consumption and ATP production in the sciatic nerve, which is associated with the reduced activity of the mitochondrial respiratory chain complex I/II (Zheng et al., 2011). Acetyl-l-carnitine, an antioxidant with protective effects on mitochondria, ameliorated oxaliplatin-induced CIPN in rats. Oxaliplatin also caused the loss of mitochondrial membrane potential in Schwann cells (Imai et al., 2017).

Oxaliplatin treatment was reported to activate nuclear factor-erythroid-2-related factor 2 (Nrf2) signaling, which plays a crucial role in mitochondrial function, and Nrf2 knockout mice developed aggravated neuropathic symptoms after oxaliplatin administration (Yang et al., 2018).

Neuronal Damage
Platinum accumulation was correlated with neuronal damage induced by oxaliplatin treatment (Holmes et al., 1998; Cavaletti et al., 2001). Several transporters were reported to be involved in platinum transport in the DRG. Among them, the overexpression of organic cation transporter 2 (OCT2) markedly increased the cellular uptake of oxaliplatin and platinum-DNA adduct formation. Importantly, genetic knockout or pharmacological inhibition of OCT2 protected mice from developing acute neuropathic symptoms after oxaliplatin administration (Sprowl et al., 2013). Surprisingly, a recent study reported that OCT2 was mainly expressed on satellite glial cells (SGCs), which suggests a critical interaction between sensory neurons and peripheral glial cells (Huang et al., 2020). However, the cell type responsible for causing oxaliplatin-mediated neuronal damage should be verified by the cell type-specific regulation of OCT2 expression with genetic modification tools. In addition, a recent study showed that organic cation/carnitine transporter 1 and multidrug and toxic compound extrusion 1 also play roles in the influx/efflux of oxaliplatin in the DRG, respectively (Jong et al., 2011; Nishida et al., 2018; Fujita et al., 2019).

Oxaliplatin uptake in the DRG results in neuronal damage, such as excessive oxidative stress followed by axonal degeneration in the sciatic nerve of rodent models. Hypomyelination was also observed in the sciatic nerve, and this reduction in myelin sheath integrity might be related to alterations in the mir-15b, β-secretase 1, and cleaved neuregulin 1 pathways (Tsutsumi et al., 2014; Ito et al., 2017).

Alteration of Central Nervous System Functions
Most chemotherapeutic drugs including oxaliplatin have limited permeability across the blood-brain barrier; however, oxaliplatin can induce central nervous system (CNS) dysfunction. Oxaliplatin increases the expression of N-methyl-d-aspartate receptor (NMDAR) followed by the phosphorylation of Ca2+/calmodulin dependent protein kinase II in the spinal cord, which might contribute to the development of oxaliplatin-induced CIPN (Mihara et al., 2011; Shirahama et al., 2012). Moreover, an increase in extracellular glutamate concentration and a decrease in glutamate transporter 1 expression were observed in the spinal cords of oxaliplatin-treated rats and were involved in the development of mechanical allodynia (Chelini et al., 2017; Yamamoto et al., 2017).

Oxaliplatin-induced CIPN might also involve astrocytic activation in the spinal cord. Activated astrocytes increase the formation of gap junctions, which might result in pain hypersensitivity (Di Cesare Mannelli et al., 2013a; Yoon et al., 2013). However, oxaliplatin-induced glial cell activation might not be severe.

Paclitaxel-Induced CIPN
Paclitaxel is an antineoplastic drug extracted from Taxus brevifolia and is used to treat several malignancies, including breast cancer, non-small cell lung carcinoma, and stomach cancer. Paclitaxel has a microtubule-targeting effect, which interferes with the construction of cell structures and function of microtubules. Microtubules have important roles in neuronal function, and thus paclitaxel often induces peripheral neuropathy. Paclitaxel administration causes ion channel dysfunction, axonal degeneration, and inflammatory events (Figure 2).

Neuronal Degeneration and Dysfunction of Axonal Transport
A recent study identified the murine solute carrier organic anion-transporting polypeptide 1B2 (OATP1B2) as a transporter that uptakes paclitaxel into DRG neurons (Leblanc et al., 2018). Inhibition of OATP1B2 prevented paclitaxel-induced sensory hypersensitivity. In paclitaxel-treated animals, the upregulation of ATF3, a marker of nerve injury, was observed in DRG neurons (Peters et al., 2007; LoCoco et al., 2017). Moreover, paclitaxel induced axonal degeneration in the sciatic nerve (Cavaletti et al., 1995). Wallerian Degeneration Slow mice are resistant to neuronal dysfunction after paclitaxel injection, indicating neurodegeneration is required for the development of paclitaxel-induced CIPN (Wang et al., 2002).

Cumulative evidence indicates that calcium-dependent calpain proteases are critical regulators leading to axonal
FIGURE 2 | Mechanisms of paclitaxel-induced peripheral neuropathy. The red up arrows indicate an increase and/or activation and the blue down arrows indicate a decrease and/or inhibition. Abbreviations: 9,10-epoxy-12Z-octadecenoic acid (9,10-EpOME); bcl-2-like protein 2 (Bclw); voltage-gated calcium channel (Cav); cytochrome-P450-epoxygenase 2J (CYP2J); interleukin (IL); inositol 1,4,5-trisphosphate receptor 1 (IP3R1); lysophosphatidic acid (LPA); voltage-gated sodium channel (Nav); organic anion-transporting polypeptide B2 (OATP1B2); P2X purinoreceptor 7 (P2X7R); sphingosine 1-phosphate (S1P); satellite glial cell (SGC); tumor necrosis factor (TNF); transient receptor potential channel (TRP).
Inflammation and Non-neuronal Cell Activation

Paclitaxel causes multiple inflammatory events compared with oxaliplatin, and a variety of non-neuronal cells contribute to its pathogenesis. In the peripheral nervous system, macrophages infiltrate into the DRG and release several inflammatory cytokines, such as tumor necrosis factor-α and interleukin-1β (IL-1β) (Ledeboer et al., 2007; Zhang et al., 2016). Macrophages and SGCs are activated by paclitaxel (Peters et al., 2007). Gap junction-mediated coupling between SGCs was increased after paclitaxel treatment and the activation of SGCs affected neuronal activity mediated by IL-17 and/or other cytokines and glial transmitters (Warwick and Hanani, 2013; Luo et al., 2019a). Recently, the dysregulation of Schwann cells was shown in paclitaxel-induced CIPN (Wozniak et al., 2018). Paclitaxel treatment impaired Schwann cells by their dedifferentiation into an immature state, which might disrupt communication between neurons and Schwann cells (Imai et al., 2017). Furthermore, the number of CD8+ T cells was increased in the DRG of paclitaxel-treated mice, contributing to recovery from neuropathic symptoms via IL-10-mediating signaling (Krukowski et al., 2016).

In the CNS, microglial and astrocytic activation occur in the spinal dorsal horn (Peters et al., 2007; Zhang et al., 2012; Luo et al., 2019a). Similar to the DRG, several inflammatory cytokines and chemokines were increased, which modulated dorsal horn neuronal activities (Li et al., 2015; Manjavachi et al., 2019). The increased expression of microglial purinoceptor P2X7 receptor enhanced CCL3-CCR5 signals involved in mechanical allodynia (Ochi-ishi et al., 2014). Several species of lipid mediator were also increased in the spinal cord in paclitaxel-induced CIPN. Lyosphosphatidic acid (LPA) and sphingosine 1-phosphate (SIP) were required for the development of paclitaxel-induced neuropathic pain via the receptors LPA1/LPA3 and SIPR1, respectively (Janes et al., 2014; Uchida et al., 2014).

Ion Channel Dysregulation

In contrast to oxaliplatin, paclitaxel indirectly alters ion channel activity by endogenous mediators and their signaling pathways, which leads to neuropathic pain. Several voltage-gated ion channels such as T-type Ca2+ channel and Na+,1,7 are involved in paclitaxel-induced CIPN. Furthermore, the inhibition of these channels attenuated mechanical allodynia (Flatters and Bennett, 2004; Li et al., 2018).

TRP channels also have important roles in paclitaxel-induced CIPN (Alessandri-Haber et al., 2004; Chen et al., 2011; Hara et al., 2013; Boehmerle et al., 2018). Agonism of kinin receptors sensitized TRP vanilloid 4 (TRPV4) via a PKC-dependent pathway, which is involved in paclitaxel-induced peripheral neuropathy (Costa et al., 2018). Paclitaxel increased several lipid metabolites in the DRG, especially 9,10-EpOME, a metabolite of linoleic acid, which was upregulated via the elevation of cytochrome-P450-epoxygenase CYP2J. Sensitization of TRPV1 channels in DRG neurons by this lipid mediator contributed to the development and maintenance of paclitaxel-induced pain hypersensitivity (Sisignano et al., 2016a). Furthermore, deficiency in another TRP channel family member, TRPM2, had a protective effect against paclitaxel-induced CIPN (So et al., 2015).

**DRUG REPOSITIONING STUDY FOR THE PREVENTION AND TREATMENT OF CIPN**

Drug development is costly and lengthy. Many novel analgesics are dropped during clinical trials because of their lack of efficacy or safety problems (Sisignano et al., 2016b). Drug repositioning has been proposed for the discovery of new uses for approved drugs; therefore, it might be an alternative strategy to the high cost and time required for drug development whilst maintaining safety. Furthermore, drug repositioning is an efficient strategy for the treatment of drug-induced adverse effects, such as CIPN.

Recently, increasing numbers of studies have reported the preventive effects of approved drugs for CIPN (Table 1). These drug repositioning studies can be divided into “mechanism-based” (known developmental mechanism of CIPN and the action mechanism of approved drugs) or “screening-based” studies (utilizing chemical libraries including approved drugs to discover the novel action of a drug for the prevention and/or treatment of CIPN).

**Mechanism-Based Strategy**

**Neuronal Damage**

CIPN induced by specific chemotherapeutic drugs is associated with neuronal damage related to sciatic nerve axonal degeneration in experimental rodent models. Several approved drugs for neurodegenerative diseases were investigated to determine whether they are useful for the prevention of chemotherapy-induced axonal degeneration and neuropathic pain. Dimethyl fumarate, a drug for multiple sclerosis, has anti-oxidative effects mediated via the Nrf2 pathway and exerts neuroprotective effects. Furthermore, dimethyl fumarate co-treatment ameliorated oxaliplatin-induced CIPN without affecting its anti-tumor activity (Miyagi et al., 2019). The acetylcholinesterase inhibitor donepezil, used for Alzheimer’s disease, was effective at preventing neuronal degeneration in *in vitro* and *in vivo* models of oxaliplatin-induced CIPN (Kawashiri et al., 2019). Acetylcholine signaling is involved in oxaliplatin- and paclitaxel-induced disorders of the nervous system (Di Cesare Mannelli et al., 2013b; Di Cesare Mannelli et al., 2014; Ferrier et al., 2015; Romero et al., 2017; Kyte et al., 2018; Toma et al., 2019). However, there are many acetylcholine-related receptor subtypes, and thus subtype-specific antagonists...
### TABLE 1 | Potential candidates of drug repositioning for CIPN identified in preclinical studies

| IDrug                        | Approved diseases                                      | Effects (Prevention or Treatment) | Proposed mechanism                                                                 | References                  |
|------------------------------|---------------------------------------------------------|-----------------------------------|------------------------------------------------------------------------------------|-----------------------------|
| Acetazolamide                 | Ectodermal dysplasia                                    | Oxaliplatin (acute)               | Inhibition of carbonic anhydrase                                                   | Potenza et al. (2020)       |
| Alogliptin                    | Type 2 diabetes mellitus                                | Oxaliplatin (chronic)             | Unknown                                                                            | Shigematsu et al. (2020)    |
| Cimetidine                   | Heartburn, peptic ulcers                                | Oxaliplatin (acute)               | Inhibition of OCT2                                                                  | Sprovl et al. (2013)        |
| Dasatinib                    | Chronic myeloid leukemia, Acute lymphoblastic leukemia  | Oxaliplatin (acute)               | Inhibition of OCT2                                                                  | Sprovl et al. (2016); Huang et al. (2020) |
| Diltiazem                    | Angina, Multiple sclerosis                              | Oxaliplatin (acute)               | Inhibition of calcium channel                                                       | Kawashiri et al. (2012)     |
| Dimethyl fumarate             | Angina, Multiple sclerosis                              | Oxaliplatin (chronic)             | Activation of Nrf2 pathway                                                         | Miyagi et al. (2018)        |
| Donepezil                    | Alzheimer’s disease                                      | Oxaliplatin (chronic)             | Attenuation of reduction of SOD activity, and Activation of acetylcholine signaling | Ferrier et al. (2015); Kawashiri et al. (2019); Flatters and Bennett (2004); Fujita et al. (2015) |
| Ethosuximide                 | Absence epilepsy                                         | Paclitaxel (chronic)              | Inhibition of calcium channel                                                       | Unknown                     |
| Exenatide                    | Type 2 diabetes mellitus                                | Paclitaxel (chronic)              | Unknown                                                                            | Unknown                     |
| Fingolimod                   | Multiple sclerosis                                       | Oxaliplatin (chronic)             | Inhibition of PDE and activation of calpain protease activity                      | Yamamoto et al. (2019)      |
| Fluvoxamine                  | Breast cancer, Tadalafl                                  | Oxaliplatin (chronic)             | Inhibition of sodium channel                                                       | Minara et al. (2011)        |
| Itenprodil                   | Dizzy after cerebral hemorrhage                         | Oxaliplatin (chronic)             | Antagonism of NMDAR                                                                | Minara et al. (2011)        |
| Budiast                      | Asthma cerebrovascular disorders                        | Paclitaxel (chronic)              | Unknown                                                                            | Egashira et al. (2010); Kawashiri et al. (2012) |
| Memantine                    | Alzheimer’s disease                                      | Oxaliplatin (chronic)             | Antagonism of NMDAR                                                                | Minara et al. (2011)        |
| Mexetine                     | Arrhythmia                                              | Oxaliplatin (acute, chronic)       | Prevention of SOCE dysregulation                                                     | Chen et al. (2017)          |
| Minoxidil                    | Hypertension                                            | Paclitaxel (acute), prevention of hair quality | Prevention of SOCE dysregulation                                                     | Prevention of SOCE dysregulation |
| Nifedipine                   | Hypertension                                            | Oxaliplatin (acute)               | Inhibition of calcium channel                                                       | Kawashiri et al. (2012)     |
| Nitotinib                    | Chronic myeloid leukemia                                 | Paclitaxel (acute)                | Inhibition of OATP1B2                                                               | Leblanc et al. (2018)       |
| Prenzepine                   | Peptic ulcer                                            | Paclitaxel (acute)                | Antagonism of muscarinic M1R                                                        | Calcetti et al. (2017)      |
| Polaprezinc                  | Peptic ulcer                                            | Paclitaxel (acute)                | Unknown                                                                            | Tsutsumi et al. (2016)      |
| Riluzole                     | Amyotrophic lateral sclerosis                           | Oxaliplatin (acute, chronic)      | Activation of TCRE-1 channel inhibition of TRPM8 activation                          | Yamamoto et al. (2017); Poupon et al. (2018); Yamamoto et al. (2018) |
| Rosiglitazone                | Type 2 diabetes mellitus                                | Paclitaxel (acute, chronic)       | Inhibition of PDE5                                                                 | Zanardelli et al. (2014)     |
| Tadalafl                     | Benign prostatic hyperplasia, Erectile dysfunction       | Paclitaxel (acute, chronic)       | Inhibition of PPARy                                                                 | Oghara et al. (2019)        |
| Telmisartan                  | Hypertension                                            | Paclitaxel (acute)                | Inhibition of CYP2J                                                                  | Sisignano et al. (2016a)    |
| Thrombomodulin               | Disseminated intravascular coagulation, Seizures         | Paclitaxel (acute, chronic)       | Degradation of HMGB1                                                                | Nichida et al. (2016); Tsubota et al. (2019) |
| Topiramate                   | Ectodermal dysplasia                                    | Paclitaxel (acute)                | Inhibition of calcium channel                                                       | Potenza et al. (2020)       |

Transporters of Chemotherapeutic Drugs

The inhibition of chemotherapeutic drug uptake into the nervous system is a promising strategy to prevent CIPN, although it is important to consider the potential effects on the anti-tumor activity. OCT2 or OATP1B2 are dominant transporters expressed in the DRG, which uptake oxaliplatin or paclitaxel, respectively. Cimetidine, a competitive inhibitor of OCT2, is approved for peptic ulcers and prevents acute cold allodynia after oxaliplatin injection (Sprovl et al., 2013). It was also reported that the tyrosine kinase inhibitor (TKI) nilotinib blocked OATP1B2 transport activity and suppressed the development of paclitaxel-induced neuropathic pain (Leblanc et al., 2018). Importantly, both OCT2 and OATP1B2 transporters are expressed at undetectable levels in tumor cell lines and tumor specimens, as confirmed by real-time PCR or RNA sequencing analysis (Sprovl et al., 2013; Leblanc et al., 2018).

Ion Channels

Based on the mechanism of TRPM8 upregulation, several ion channel inhibitors were examined for the prevention of oxaliplatin-induced cold allodynia. The co-administration of the L-type Ca^2+ channel blockers, nifedipine and diltiazem, but not the T-type calcium channel inhibitor...
ethosuximide, prevented cold allodynia caused by oxaliplatin (or oxalate). In addition, the Na\(^+\) channel inhibitor mexiteline also prevented cold allodynia. These preventive effects were related to the inhibition of the Ca\(^{2+}/NFAT/\)diltiazem, had a lower incidence of oxaliplatin-induced channel blockers including nifedipine, amlodipine, and diltiazem, had a lower incidence of oxaliplatin-induced cold hypersensitivity compared with 43 control patients \((p = 0.0438)\) (Tatsushima et al., 2013).

Topiramate and acetazolamide are known inhibitors of carbonic anhydrase, which facilitates intracellular pH homeostasis. These approved drugs inhibit cytosolic pH lowering and sensitization of TRPA1 by oxaliplatin, potentially prevent oxaliplatin-induced cold allodynia (Potenzieri et al., 2020).

**Glutamate Signaling**

Riluzole is a potential candidate for the prevention of oxaliplatin-induced CIPN via multiple mechanisms. Riluzole modulates the activities of several ion channels including TRPM8 and TREK1 and thus suppresses cold allodynia (Poupon et al., 2018; Yamamoto et al., 2018). In addition, oxaliplatin failed to disrupt glutamate homeostasis in the spinal cord after co-treatment with riluzole, which prevented oxaliplatin-induced mechanical allodynia (Yamamoto et al., 2017). Importantly, riluzole prevented oxaliplatin-induced morphological abnormalities of DRG neurons. In a recent study, riluzole co-administration was not effective against oxaliplatin-induced neuropathy (Trinh et al., 2020). However, this clinical trial had a limited sample size (placebo: 23 patients, riluzole: 25 patients), which means that further large-scale clinical studies are needed to clarify the effect of riluzole. The RILUZOX-01 study, a randomized, controlled, double-blind phase II clinical trial to evaluate the efficacy of riluzole on oxaliplatin-induced CIPN, is ongoing at present (Kerckhove et al., 2019).

Including riluzole, the treatment focused on the disruption of glutamate homeostasis and excessive signaling pathways in the CNS as potential strategies to treat CIPN. Several approved drugs such as memantine and ifenprodil have demonstrated efficacy in oxaliplatin-induced CIPN, especially mechanical allodynia, via the inhibition of NMDAR activity (Mihara et al., 2011; Shirahama et al., 2012).

**Others**

Cumulative evidence has indicated the pleiotropic effects of anti-diabetic drugs, especially glucagon-like peptide-1 (GLP-1)-related drugs such as GLP-1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Several studies examined whether exenatide and alogliptin had beneficial effects against chemotherapy-induced neurodegeneration and neuropathic pain and demonstrated that these approved drugs attenuated axonal degeneration and mechanical allodynia after oxaliplatin administration in rats (Fujita et al., 2015; Shigematsu et al., 2020).

**Screening-Based Strategy**

Over the last 5–10 years, approved drug-containing chemical libraries have been widely used to explore unknown pharmacological functions. One of the hallmarks of CIPN is axonal degeneration, which is reproduced in in vitro cellular models in the form of shortened neurite length or reduced neurite branches. Using in vitro models, several drug repositioning studies have discovered unexpected the neuroprotective effects of approved drugs.

**Neuroprotective Drug**

Fulvestrant, for the treatment of breast cancer, was screened from several small-molecule chemical libraries including more than 3,000 compounds and reduced oxaliplatin-induced neuronal damage in a cellular model (Yamamoto et al., 2019). Consistent with these in vitro effects, fulvestrant also exerted neuroprotective effects in an oxaliplatin-CIPN rodent model, by preventing sciatic nerve axonal degeneration and the development of mechanical allodynia (Yamamoto et al., 2019). However, the mechanism of this neuroprotective effect remains unclear. In a similar approach, minoxidil and pirenzepine, approved drugs for hypertension and alopecia, and peptic ulcers, respectively, were shown to be neuroprotective. Minoxidil has neuroprotective effects against paclitaxel in primary cultured DRG neurons and alleviated paclitaxel-induced CIPN by inhibiting neuroinflammation and remodeling the dysregulation of intracellular calcium homeostasis in DRG neurons (Chen et al., 2017). Minoxidil also improved hair quality after paclitaxel administration. Pirenzepine protected mice from peripheral neurodegeneration caused by chemotherapy, diabetes, and HIV envelope protein gp120 by antagonizing the muscarinic acetylcholine type 1 receptor, leading to improved mitochondrial dysfunction (Calcutt et al., 2017).

**Inhibitor of OCT2 Transporter Activity**

The screening of a large-scale bioactive compound library (8,086 compounds) identified the FDA-approved TKI dasatinib as a potent inhibitor of the OCT2 transporter, which is involved in oxaliplatin uptake to the DRG (Sprawl et al., 2016). OCT2 requires Yes1-mediating tyrosine phosphorylation; therefore, dasatinib treatment is sufficient to inhibit platinum accumulation in the DRG, which mitigates oxaliplatin-induced neuropathic pain.

**Inhibitor of CYP2J Enzymatic Activity**

Sisignano et al. reported paclitaxel treatment increased CYP2J expression in the DRG, which increased the levels of pronociceptive oxidized lipid mediators. Drug repositioning screening identified telmisartan, a widely-used angiotensin II receptor antagonist for hypertension, as a potent inhibitor of CYP2J, which prevents and reverses paclitaxel-induced neuropathic pain. In contrast, olmesartan, which belongs to the same pharmacological group, had no effect on CYP2J activity (Sisignano et al., 2016a). In addition, telmisartan is established as a selective antagonist of angiotensin II type 1 receptor, despite evidence that the similar drug candesartan
exerts neuroprotective effects against vincristine-induced neuropathy via the angiotensin II type 2 receptor (Bessauguet et al., 2018). Thus, the analgesic effect of telmisartan may not be derived from its action on the angiotensin receptor.

**Future Expectations**

**Lipid-Related Molecules**

Numerous mechanisms involved in CIPN have been revealed in recent years, and these might become potential therapeutic targets over the next decade. Biological lipids and related molecules are one of the most intriguing targets of drug discovery for CIPN prevention and treatment. In addition to telmisartan, fingolimod, an approved drug for the treatment of multiple sclerosis that modulates the S1P receptor, was also shown to be effective against paclitaxel-induced neuropathic pain (Janes et al., 2014). Furthermore, stimulation of cannabinoid type 2 receptor (CB2) exerted an analgesic effect against CIPN (Naguib et al., 2008; Rahn et al., 2008; Deng et al., 2015). The endocannabinoid 2-arachidonyleglycerol, a ligand for CB2, is biosynthesized from membrane phospholipids and degraded by monoacylglycerol lipase. Similar to CB2 agonists, monoacylglycerol lipase inhibitors have a potential analgesic effect on chemotherapy-induced neuropathic pain (Brindisi et al., 2016; Curry et al., 2018). Therefore, based on these well-studied molecules, mechanism-based repositioning screening might identify and reposition many approved drugs as novel analgesics or novel preventative drugs for CIPN.

**Fatty Acid-Derived Mediators**

Omega-3 fatty acid and its related mediators also have antinociceptive properties. Although the effects of most of these mediators have been examined using nerve injury-induced neuropathic pain or inflammatory pain models, but not CIPN, they were shown to be effective against refractory pain syndromes (Xu et al., 2010; Ji et al., 2011; Xu et al., 2013). In particular, Serhan and colleagues identified new families of potent anti-inflammatory lipid mediators derived from omega-3 fatty acid, called “specialized pro-resolving mediators” (SPMs), which include resolvins, neuroprotectin, and maresins (Serhan et al., 2002; Serhan et al., 2008; Chen et al., 2018). SPMs have a wide range of analgesic effects against a variety of types of chronic pain. Among the docosahexaenoic acid metabolite series, the intrathecal injection of resolvin D1 (RvD1), RvD2, and RvD5 reduced paclitaxel-induced mechanical allodynia, which might be related to their inhibition of TRPV1 and/or TRPA1 (Luo et al., 2019b). Therefore, biological lipid mediators (especially SPMs) or lipid-related molecules (such as receptors and enzymes) are potential targets for the treatment of CIPN. However, not all omega-3 related mediators are anti-inflammatory. For example, an eicosapentaenoic acid-derived mediator 17,18-EEQ, sensitized TRPV1 and TRPA1 in a prostaglandin receptor IP-dependent manner (Schafer et al., 2020).

**Stem Cells**

The utilization of stem cell-derived neurons has increased (Wainger et al., 2015; Schwartzzentuber et al., 2018; Mis et al., 2019). Dolan et al. established a chemotherapy-induced neurotoxicity *in vitro* model using induced pluripotent stem cells differentiated into neurons (Wheeler et al., 2015; Wing et al., 2017). Although hydroxyurea and 5-fluorouracil, not known to cause CIPN, did not affect neurite morphology in this model, platinum agents, taxanes, and bortezomib reduced neurite outgrowth and processes, suggesting induced pluripotent stem cell-derived neurons might be useful for the screening of potential neuroprotective drug candidates. Thus, if patient-derived sensory neurons become easily available and are actively utilized in clinical practice, tailored therapy individualized for each patient could be realized, by screening and searching for drugs effective against CIPN. Furthermore, the intravenous injection of rat adipose-derived stem cells attenuated oxaliplatin-induced pain hypersensitivity in a rat model, and this analgesic effect lasted for 5 days (Di Cesare Mannelli et al., 2018). Thus, the utilization of stem cells including the injection of adipose-derived stem cells might be a novel therapeutic strategy. In addition, the elucidation of mechanisms related to this analgesic effect might enhance the analgesic efficacy of approved drugs.

**Consideration for Oncological Safety**

The drug repositioning studies reviewed here indicate that several approved drugs may have beneficial effects against CIPN in rodent models. However, careful attention to oncological safety with respect to interactions with both cancer cells and anticancer drugs is required when drugs are co-administered with neurotoxic anticancer drugs. Although most of the potential therapies reviewed here, particularly those for preventive use, have shown no effect on the anticancer activity of chemotherapeutic drugs in cancer cell lines or in tumor bearing animals, newly developed preventive and/or treatment strategy should be considered for translation into clinical practice.

**CONCLUSIONS**

The prevention and treatment of existing CIPN remain unmet clinical needs. Recent studies have shown the involvement of a number of potential target molecules such as chemotherapeutic agent-uptake transporters (OCT2 and OATP1B2) and CYP2J, in the development of CIPN. Furthermore, drug repositioning studies have demonstrated the efficacy of several approved drugs such as TKIs, GLP-1-related agents, riluzole, and others, in rodent models of CIPN.

Drug repositioning studies are useful for demonstrating the action of a drug against CIPN, investigating the mechanisms of approved drugs, and discovering unexpected actions of approved drugs by the screening of chemical libraries. In addition, the screening of chemical libraries might help elucidate the mechanisms of CIPN, especially when investigating neuroprotective drugs. The known actions of hit compounds in neurodegenerative phenotypic assays might indicate how neurodegeneration occurs after chemotherapy.

Recent studies have reported potential therapeutic targets for CIPN including endogenous lipid-related molecules (such as...
SPMs), and the use of stem cells. In addition to the treatment of existing neuropathies, future trials should test drugs for the prevention of CIPN. The preclinical evidence reviewed here should be assessed in clinical trials, which we hope will result in the improved quality of life of cancer patients.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

REFERENCES

Alessandri-Haber, N., Dina, O. A., Yeh, J. J., Parada, C. A., Reichling, D. B., and Levine, J. D. (2004). Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat. J. Neurosci. 24 (18), 4444–4452. doi:10.1523/JNEUROSCI.0242-04.2004

Bessaquet, F., Danigo, A., Bouchenaki, H., Duchesne, M., Magy, L., Richard, L., et al. (2018). Neuroprotective effect of angiotensin II type 2 receptor stimulation in vincristine-induced mechanical allodynia. Pain 159 (12), 2538–2546. doi:10.1097/PAIN.0000000000001931

Bobylev, I., Joshi, A. R., Barham, M., Ritter, C., Neiss, W. F., Hoke, A., et al. (2015). Paclitaxel inhibits mRNA transport in axons. Neurobiol. Dis. 82, 321–331. doi:10.1016/j.nbd.2015.07.006

Boehmerle, W., Huehnchen, P., Lee, S. L. L., Harms, C., and Endres, M. (2018). TRPV4 inhibition prevents paclitaxel-induced neurotoxicity in preclinical models. Exp. Neurol. 306, 64–75. doi:10.1016/j.expneurol.2018.04.014

Boehmerle, W., Zhang, K., Sivula, M., Heidrich, F. M., Lee, Y., Jordt, S. E., et al. (2018). Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation. Proc. Natl. Acad. Sci. U.S.A. 104 (26), 11103–11108. doi:10.1073/pnas.0701546104

Breuer, J. R., Morrison, G., Dolan, M. E., and Fleming, G. F. (2016). Chemotherapy-induced peripheral neuropathy: current status and progress. Gynecol. Oncol. 140 (1), 176–183. doi:10.1016/j.ygyno.2015.11.011

Brindisi, M., Maramai, S., Gemma, S., Brogi, S., Grillo, A., Di Cesare Mannelli, L., et al. (2016). Development and pharmacological characterization of selective blockers of 2-arachidonoyl glycerol degradation with efficacy in rodent models of multiple sclerosis and pain. J. Med. Chem. 59 (6), 2612–2632. doi:10.1021/acs.jmedchem.5b01812

Calcutt, N. A., Smith, D. R., Frizzi, K., Sabbir, M. G., Chowdhury, S. K., Mixcoatl-Cavaletti, G., Tredici, G., Braga, M., and Tazzari, S. (1995). Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of oxaliplatin. Neuropharmacology 34 (12), 1661–1667. doi:10.1016/0028-3908(95)90080-9

Chelini, A., Brogi, S., Paolino, M., Di Capua, A., Cappelli, A., Giorgi, G., et al. (2017). Synthesis and biological evaluation of novel neuroprotective pyridazine derivatives as excitatory amino acid transporter 2 (EAAT2) activators. J. Med. Chem. 60 (12), 5216–5221. doi:10.1021/acs.jmedchem.7b00383

Chen, G., Zhang, Y. Q., Qadri, Y. J., Serhan, C. N., and Ji, R. R. (2018). Microglia in pain: detrimental and protective roles in pathogenesis and resolution of pain. Neuron 100 (6), 1292–1311. doi:10.1016/j.neuron.2018.11.009

Chen, Y., Yang, C., and Wang, Z. J. (2011). Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience 193, 440–451. doi:10.1016/j.neuroscience.2011.06.085

Chen, Y. F., Chen, L. H., Yeh, Y. M., Wu, P. Y., Chen, Y. F., Chang, L. Y., et al. (2017). Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy. Sci. Rep. 7, 45366. doi:10.1038/srep45366

Colloca, L., Ludman, T., Bouhassira, D., Baron, R., Dickinson, A. H., Yarnitsky, D., et al. (2017). Neuropathic pain. Nat Rev Dis Primers 3, 17002. doi:10.1038/nrdp.2017.12

Costa, R., Bica, M. A., Manjavachi, M. N., Segat, G. C., Dias, F. C., Fernandes, E. S., et al. (2018). Kinin receptors sensitize TRPV4 channel and induce mechanical hyperalgesia: relevance to paclitaxel-induced peripheral neuropathy in mice. Mol. Neurobiol. 55 (3), 2150–2161. doi:10.1007/s12051-017-0475-9

Curry, Z. A., Wilkerson, J. L., Bagdas, D., Kyte, S. L., Patel, N., Donvito, G., et al. (2018). Monocacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathic injury. J. Pharmacol. Exp. Therapeut. 366 (1), 169–183. doi:10.1124/jpet.117.245704

Deng, L., Cornett, B. L., Mackie, K., and Hohmann, A. G. (2015). CB1 knockout mice unveil sustained CB2-mediated antiallodynic effects of the mixed CB1/ CB2 agonist CP55,940 in a mouse model of paclitaxel-induced neuropathic pain. Mol. Pharmacol. 88 (1), 64–74. doi:10.1124/jpet.115.2015.028997

Descoeur, J., Pereira, V., Pizzoccaro, A., Francois, A., Ling, B., Maffre, V., et al. (2011). Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol. Med. 3 (5), 266–278. doi:10.1002/emmm.201100134

Di Cesare Mannelli, L., Pacini, A., Bonaccini, L., Zanardelli, M., Mello, T., and Ghelardini, C. (2013a). Morphologic features and glial activation in rat oxaliplatin-dependent neuropathic pain. J. Pain 14 (2), 1585–1600. doi:10.1097/j.pain.0b013e31828e9dcd

Di Cesare Mannelli, L., Pacini, A., Matera, C., Zanardelli, M., Mello, T., De Amici, M., et al. (2014). Involvement of α7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation. Neuropharmacology 79, 37–48. doi:10.1016/j.neuropharm.2013.10.034

Di Cesare Mannelli, L., Tenci, B., Micheli, L., Vona, A., Corti, F., Zanardelli, M., et al. (2018). Adipose-derived stem cells decrease pain in a rat model of oxaliplatin-induced neuropathy: role of VEGF-A modulation. Neuropharmacology 131, 166–175. doi:10.1016/j.neuropharm.2017.12.020

Di Cesare Mannelli, L., Zanardelli, M., and Ghelardini, C. (2013b). Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models. Eur. J. Pharmacol. 711 (1–3), 87–94. doi:10.1016/j.ejphar.2013.04.022

Durand, J. P., Deplanque, G., Montheil, V., Gornet, J. M., Scott, F., Mir, O., et al. (2012). Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann. Oncol. 23 (1), 200–205. doi:10.1093/annonc/mdr045

Egashira, N., Hirakawa, S., Kawashiri, T., Yano, T., Ikuse, H., and Oishi, R. (2010). Mexiletine reverses oxaliplatin-induced peripheral neuropathic pain in rats. J. Pharmacol. Sci. 112 (4), 473–476. doi:10.1254/jps.10012sc

El-Fatayri, Y. M., Ibrahim, O. M., Hussien, F. Z., and Mostafa, T. M. (2018). Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage

FUNDING

This work was supported by JSPS KAKENHI Grant Numbers JP19K16938 (SY) and JP17K08953 (NE).

ACKNOWLEDGMENTS

We thank J. Ludovic Croxford, PhD, and Clare Cox, PhD, from Edanz Group (https://en-author-services.edanzgroup.com/ac) for editing a draft of this manuscript.
Miyake, T., Nakamura, S., Zhao, M., So, K., Inoue, K., Numata, T., et al. (2016). Cold sensitivity of TRPA1 is unveiled by the prolyl hydroxylation blockade-induced sensitization to ROS. Nat. Commun. 7, 12840. doi:10.1038/ncomms12840

Mo, M., Erdelyi, I., Szigeti-Buck, K., Benbow, J. H., and Ehrlich, B. E. (2012). Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment. Faseb. J. 26 (11), 4696–4709. doi:10.1096/fj.12-214643

Naguib, M., Diaz, P., Xu, J. J., Aastrup-Diaz, F., Craig, S., Vivas-Mejia, P., et al. (2008). MDA7: a novel selective agonist for CR2 receptors that prevents allodynia in rat neuropathic pain models. Br. J. Pharmacol. 155 (7), 1104–1116. doi:10.1111/j.1476-5381.2008.03430.x

Nassini, R., Gees, M., Harrison, S., De Siena, G., Materazzi, S., Moretti, N., et al. (2011). Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 152 (7), 1621–1631. doi:10.1016/j.pain.2011.02.051

Nishida, K., Takeuchi, K., Hosoda, A., Sugano, S., Morisaki, E., Ohishi, A., et al. (2018). Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats. Life Sci. 207, 516–526. doi:10.1016/j.lfs.2017.08.006

Nishida, T., Tsubota, M., Kawai, Y., Yanamashi, H., Kamiyama, N., Sekiguchi, F., et al. (2016). Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. Toxicology 365, 48–58. doi:10.1016/j.tox.2016.07.016

Ochi-Ishi, R., Nagata, K., Inoue, T., Tozaki-Saitoh, H., Tsuda, M., and Inoue, K. (2014). Role of the TREK2 potassium channel in cold and warm thermosensation and in pain perception. Proc. Natl. Acad. Sci. U.S.A. 111 (4), 15084. doi:10.1073/pnas.1315081110

Sakurai, M., Egashira, N., Kawashiri, T., Yano, T., Ikose, H., and Oishi, R. (2009). Oxaliplatin-induced neuropathy in the rat: involvement of oxolate in cold hyperalgesia but not mechanical allodynia. Pain 147 (1–3), 165–174. doi:10.1016/j.pain.2009.09.003

Schafer, S. M. G., Sendetski, M., Angioni, C., Nusing, R., Geisslinger, G., Scholich, K., et al. (2020). The omega-3 lipid 17,18-EEQ sensitizes TRPV1 and TRPA1 in sensory neurons through the prostacyclin receptor (IP). Neuropharmacology 166, 107952. doi:10.1016/j.neuropharm.2020.107952

Schwartzentruber, J., Koskolu, S., Kilpinen, H., Rodrigues, J., Alasoo, K., Knights, A. J., et al. (2018). Molecular and functional variation in iPSC-derived sensory neurons. Nat. Genet. 50 (1), 54–61. doi:10.1038/s41588-017-0005-8

Serhan, C. N., Chiang, N., and Van Dyke, T. E. (2008). Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8 (5), 349–361. doi:10.1038/nri2294

Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., et al. (2002). Resolving a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196 (8), 1025–1037. doi:10.1084/jem.20020760

Shigematsu, N., Kawashiri, T., Kobayashi, D., Shimizu, S., Mine, K., Hiromoto, S., et al. (2010). Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro. Sci. Rep. 10 (1), 6734. doi:10.1038/s41598-018-26275-w

Shirahama, M., Ushio, S., Egashira, N., Yamamoto, S., Sada, H., Masuguchi, K., et al. (2012). Inhibition of Ca2+/calmodulin-dependent protein kinase II reverses oxaliplatin-induced mechanical allodynia in rats. Mol. Pain 8, 26. doi:10.1186/1744-8069-8-26

Sisignano, M., Angioni, C., Park, K. C., Meyer Dos Santos, S., Jordan, H., Kuzikov, S., et al. (2016a). Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy. Exp. Neurol. 1037, 10880. doi:10.1016/j.expneurol.2015.11.006

Smith, J. A., Slusher, B. S., Wozniak, K. M., Farah, M. H., Smiyun, G., Wilson, L., et al. (2016). Structural basis for induction of peripheral neuropathy by microtubule-targeting cancer drugs. Cancer Res 76 (17), 5115–5123. doi:10.1158/0008-5472.CAN-15-3116

So, K., Harper-Kuchi, K., Asakura, K., Isami, K., Sakimoto, S., Shirakawa, H., et al. (2015). Involvement of TRPM2 in a wide range of inflammatory and neuropathic pain mouse models. J. Pharmacol. Sci. 127 (3), 237–243. doi:10.1016/j.jphs.2014.10.003

Sisignano, M., Ciarniboli, G., Lancaster, C. S., Giovinazzo, H., Gibson, A. A., Du, G., et al. (2013). Oxaliplatin-induced neuropathy is dependent on the organic cation transporter OCT2. Proc. Natl. Acad. Sci. U.S.A. 110 (27), 11199–11204. doi:10.1073/pnas.1305321110

Sjöwall, J., Ong, S. S., Gibson, A. A., Hu, S., Du, G., Lin, W., et al. (2016). A phosphotyrosine switch regulates organic cation transporters. Nat. Commun. 7, 10880. doi:10.1038/ncomms10880

Tatsushima, Y., Egashira, N., Narishige, Y., Fukushima, K., Kawashiri, T., Yamauchi, Y., et al. (2013). Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy. Biomed. Pharmacother. 67 (1), 39–42. doi:10.1016/j.biopha.2012.10.006

Toma, W., Kyte, S. L., Bagdas, D., Jackson, A., Meade, J. A., Rahman, F., et al. (2019). The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal. Exp. Neurol. 320, 113010. doi:10.1016/j.expneurol.2019.113010

Trevisan, G., Materazzi, S., Fusì, C., Altomare, A., Aldini, G., Lodovici, M., et al. (2013). Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. Cancer Res 73 (10), 3120–3131. doi:10.1158/0008-5472.CAN-12-4370

Frontiers in Pharmacology | www.frontiersin.org 12 January 2021 | Volume 11 | Article 607780

Yamamoto and Egashira

Progress for CIPN Treatment
Trinh, T., Park, S. B., Murray, J., Pickering, H., Lin, C. S., Martin, A., et al. (2020). Neu-horizonic neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial. Support Care Cancer. doi:10.1007/s00520-020-05591-x

Tsutsumi, M., Fukuda, R., Hayashi, Y., Miyazaki, T., Ueda, S., Yamashita, R., et al. (2019). Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anti-coagulants. J. Neuroinflammation 16 (1), 199. doi:10.1186/s12974-019-1581-6

Tsutsumi, K., Kaname, T., Shiraiishi, H., Kawashiri, T., and Egashira, N. (2016). Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity. J. Pharmacol. Sci. 131 (2), 146–149. doi:10.1016/j.jpbs.2016.04.019

Tsutsumi, K., Yamashita, Y., Usui, S., Kawashiri, T., Kaname, T., Fujita, S., et al. (2014). Oxaliplatin induces hypomyelination and reduced neuregulin 1 expression in the rat sciatic nerve. Neurosci. Res. 80, 86–90. doi:10.1016/j.neures.2014.02.004

Uchida, H., Nagai, J., and Ueda, H. (2014). Lysophosphatidic acid and its receptors. Frontiers in Pharmacology | www.frontiersin.org January 2021 | Volume 11 | Article 607780

Wainger, B. J., Buttermore, E. D., Oliveira, J. T., Mellin, C., Lee, S., Saber, W. A., et al. (2016). Polaprezinc inhibits RvE1 and RvD1-mediated paclitaxel-induced neuropathy. Cell Death Dis. 7, doi:10.1038/cddis.2016.315

Wing, C., Komatsu, M., Delaney, S. M., Krause, M., Wheeler, H. E., and Dolan, M. E. (2015). Acute cold hypersensitivity characteristically induced by oxaliplatin is prevented using nociceptor neurons reprogrammed from fibroblasts. Nat. Neurosci. 18 (1), 17–24. doi:10.1038/nn.3886

Wang, M. S., Davis, A. A., Culver, D. G., and Glass, J. D. (2002). WdRs mice are resistant to paclitaxel (taxol) neuropathy. Ann. Neurol. 52 (4), 442–447. doi:10.1002/ana.10300

Wang, M. S., Davis, A. A., Culver, D. G., Wang, Q., Powers, J. C., and Glass, J. D. (2004). Calpain inhibition protects against Taxol-induced sensory neuropathy. Brain 127 (Pt 3), 671–679. doi:10.1093/brain/awh078

Warwick, R. A., and Hanani, M. (2013). The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. Eur. J. Pain 17 (4), 571–580. doi:10.1002/ejp.2113-2149.2012.00219.x

Wheeler, H. E., Wing, C., Delaney, S. M., Komatsu, M., and Dolan, M. E. (2015). Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells. PLoS One 10 (2), e0118020. doi:10.1371/journal.pone.0118020

Wing, C., Komatsu, M., Delaney, S. M., Krause, M., Wheeler, H. E., and Dolan, M. E. (2017). Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy. Stem Cell Res. 22, 79–88. doi:10.1016/j.scr.2017.06.006

Wozniak, K. M., Vornov, J. J., Wu, Y., Liu, Y., Carozzi, V. A., Rodriguez-Menendez, V., et al. (2018). Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery. Cancer Res 78 (5), 817–829. doi:10.1158/0008-5472.CAN-17-1467

Xiao, W. H., Zheng, H., and Bennett, G. J. (2012). Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neurosci. Res 203, 194–206. doi:10.1016/j.neures.2011.12.023

Xu, Z. Z., Berta, T., and Ji, R. R. (2013). Resolvin E1 inhibits neuropathic pain and spinal cord microglial activation following peripheral nerve injury. J. Neuroimmune Pharmacol. 8 (1), 37–41. doi:10.1007/s11481-012-9394-8

Xu, Z. Z., Zhang, L., Liu, T., Park, J. Y., Berta, T., Yang, R., et al. (2010). Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 16 (5), 592–597. doi:10.1038/nm.2123

Yang, Y., Luo, L., Cai, X., Fang, Y., Wang, J., Chen, G., et al. (2018). Nrf2 inhibits oxaliplatin-induced peripheral neuropathy via protection of mitochondrial function. Free Radic. Biol. Med. 120, 13–24. doi:10.1016/j.freeradbiomed.2018.03.007

Yoon, S. Y., Robinson, C. R., Zhang, H., and Dougherty, P. M. (2013). Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity. J. Pain 14 (2), 205–214. doi:10.1016/j.jpain.2012.11.002

Zanardelli, M., Micheli, L., Cinci, L., Failli, P., Ghelardini, C., and Di Cesare Mannelli, L. (2014). Oxaliplatin neurotoxicity involves peroxisome alterations. PPARγ agonism as preventive pharmacological approach. PLoS One 9 (7), e102758. doi:10.1371/journal.pone.0102758

Zheng, H., Li, Y., de Carvalho-Barbosa, M., Kavelaars, A., Heijnen, C. J., Albrecht, P. J., et al. (2016). Dorsal root ganglion infiltration by macrophages contributes to paclitaxel chemotherapy-induced peripheral neuropathy. J. Pain 17 (7), 775–786. doi:10.1016/j.jpain.2016.02.011

Zhang, H., Yoon, S. Y., Zhang, H., and Dougherty, P. M. (2012). Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. J. Pain 13 (3), 293–303. doi:10.1016/j.jpain.2011.12.002

Zhao, M., Isami, K., Nakamura, S., Shirakawa, H., Nakagawa, T., and Kaneko, S. (2012). Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. Mol. Pain 8, 55. doi:10.1186/1744-8069-8-55

Zheng, H., Xiao, W. H., and Bennett, G. J. (2011). Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp. Neuropl. 232 (2), 154–161. doi:10.1016/j.expneur.2011.08.016

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yamamoto and Egashira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.